Expert opinion on pharmacotherapy · 2011
Treatment of chronic myeloid leukemia when imatinib fails.
СтатьяПоддержка исследования: вне правительства СШАОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hehlmann Rüdiger, Jung-Munkwitz Susanne, Saussele Susanne
Аннотация
INTRODUCTION: Imatinib failure represents a major clinical challenge in the management of chronic myeloid leukemia.
AREAS COVERED: Definition of failure, its causes, the various approaches to the treatment of imatinib failure such as imatinib dose escalation, second-generation tyrosine kinase inhibitors and stem cell transplantation, and monitoring of residual disease are covered in this review. Selected investigational agents and the management of blast crisis are also reviewed. After reading the review the reader will understand how to manage imatinib failure.
EXPERT OPINION: Imatinib failure can be managed in most cases by a careful appraisal of its causes and a rational selection of treatment options.
AREAS COVERED: Definition of failure, its causes, the various approaches to the treatment of imatinib failure such as imatinib dose escalation, second-generation tyrosine kinase inhibitors and stem cell transplantation, and monitoring of residual disease are covered in this review. Selected investigational agents and the management of blast crisis are also reviewed. After reading the review the reader will understand how to manage imatinib failure.
EXPERT OPINION: Imatinib failure can be managed in most cases by a careful appraisal of its causes and a rational selection of treatment options.